GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anavex Life Sciences Corp (STU:12X1) » Definitions » Debt-to-Revenue

Anavex Life Sciences (STU:12X1) Debt-to-Revenue : N/A (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Anavex Life Sciences Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Anavex Life Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.00 Mil. Anavex Life Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.00 Mil. Anavex Life Sciences's annualized Revenue for the quarter that ended in Mar. 2024 was €0.00 Mil.


Anavex Life Sciences Debt-to-Revenue Historical Data

The historical data trend for Anavex Life Sciences's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anavex Life Sciences Debt-to-Revenue Chart

Anavex Life Sciences Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Anavex Life Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Anavex Life Sciences's Debt-to-Revenue

For the Biotechnology subindustry, Anavex Life Sciences's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anavex Life Sciences's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Anavex Life Sciences's Debt-to-Revenue falls into.



Anavex Life Sciences Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Anavex Life Sciences's Debt-to-Revenue for the fiscal year that ended in Sep. 2023 is calculated as

Anavex Life Sciences's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Anavex Life Sciences Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Anavex Life Sciences's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Anavex Life Sciences (STU:12X1) Business Description

Traded in Other Exchanges
Address
630 5th Avenue, 20th Floor, New York, NY, USA, 10111
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.

Anavex Life Sciences (STU:12X1) Headlines

No Headlines